PathMaker Neurosystems Announces Issuance of Three Patents Protecting the Use of Company’s Proprietary Neuromodulation Technology in ALS
05 mars 2025 06h00 HE
|
PathMaker Neurosystems Inc.
PathMaker Neurosystems Announces Issuance of Three Patents Protecting the Use of Company’s Proprietary Neuromodulation Technology in ALS
PathMaker Neurosystems Welcomes Pritesh Shah to Board of Directors
26 févr. 2025 06h00 HE
|
PathMaker Neurosystems Inc.
PathMaker Welcomes Pritish Shah to Board of Directors
PathMaker Neurosystems Announces IRB Approval for DoD-funded Clinical Trial of the MyoRegulator Device in ALS
04 févr. 2025 06h00 HE
|
PathMaker Neurosystems Inc.
PathMaker Neurosystems Announces IRB Approval for DoD-funded Clinical Trial of the MyoRegulator® Device in ALS which will take place at BIDMC in Boston
PathMaker Neurosystems Announces $2.16 Million Award from U.S. Department of Defense for ALS Clinical Trial
05 juin 2024 06h00 HE
|
PathMaker Neurosystems Inc.
PathMaker Neurosystems receives $2.16 million award from United States Department of Defense for an expanded ALS clinical trial of its MyoRegulator device
PathMaker Neurosystems Announces Initiation of First-in-Human Trial in ALS for Non-Invasive Neuromodulation Device
14 sept. 2023 06h00 HE
|
PathMaker Neurosystems Inc.
BOSTON and PARIS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the...
PathMaker Neurosystems Receives $200,000 START Award from MassVentures
05 juin 2023 06h00 HE
|
PathMaker Neurosystems Inc.
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of...
Muscular Dystrophy Association Awards Venture Philanthropy Funding to PathMaker Neurosystems to Develop Neuromodulation Treatment for ALS
17 janv. 2023 06h00 HE
|
PathMaker Neurosystems Inc.
BOSTON and NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) and PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company...
PathMaker Neurosystems Receives $100,000 START Award from MassVentures
08 juin 2022 07h00 HE
|
PathMaker Neurosystems Inc.
BOSTON, June 08, 2022 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of...
PathMaker Neurosystems Initiates U.S. Multi-Center Trial Evaluating MyoRegulator® for the Non-Invasive Treatment of Post-Stroke Spasticity
07 mars 2022 06h00 HE
|
PathMaker Neurosystems Inc.
BOSTON and PARIS, March 07, 2022 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc., (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the...
PathMaker Neurosystems Awarded CERF Medical Electronics Prize for Amyotrophic Lateral Sclerosis
07 févr. 2022 06h00 HE
|
PathMaker Neurosystems Inc.
BOSTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of...